Other cardiovascular-pathogenic GPCR autoantibodies

Other cardiovascular-pathogenic GPCR autoantibodies refers to a group of functional immunoglobulins that target G protein-coupled receptors (GPCRs) involved in cardiovascular regulation, excluding the primary beta-1 adrenergic receptor autoantibodies (Boivin-Jahns et al., 2018). This group includes autoantibodies against the alpha-1 adrenergic, beta-2 adrenergic, muscarinic M2, angiotensin II type 1 (AT1), and endothelin A (ETA) receptors (Becker et al., 2020). These autoantibodies often act as agonists, leading to chronic overstimulation of their target receptors, which results in cardiomyocyte damage, fibrosis, and vascular dysfunction (Wallukat et al., 2010). Such pathological processes contribute to the development and progression of heart failure, dilated cardiomyopathy, and hypertension (Boivin-Jahns et al., 2018). Therapeutic strategies like the DNA aptamer BC 007 are designed to neutralize these autoantibodies by binding to them and preventing their interaction with the receptors (Becker et al., 2020). This broad-spectrum neutralization approach aims to halt the progression of cardiovascular damage and has also shown promise in treating conditions like Long COVID and ME/CFS, where these autoantibodies are frequently detected (Frontiers in Medicine, 2021). Clinical monitoring of these autoantibodies is typically performed using specialized bioassays or ELISAs to assess their functional activity and titer in patient serum (Boivin-Jahns et al., 2018). The removal of these antibodies via immunoadsorption has also demonstrated clinical benefits in patients with advanced heart failure (Wallukat et al., 2010).

Other names

Pathogenic GPCR autoantibodiesFunctional GPCR autoantibodiesVasoactive GPCR autoantibodiesfGPCR-AAbCardiovascular-pathogenic GPCR autoantibodies

Neutralization of pathogenic autoantibodies by binding to their variable regions, preventing them from interacting with and activating G protein-coupled receptors (Becker et al., 2020).